Market Overview

Bank of America Reviews a Survey on Auxilium Pharmaceutical


Bank of America has published a report on Auxilium Pharmaceuticals (NASDAQ: AUXL) reviewing the results of a survey the bank had commissioned.

In the report, Bank of America wrote, "We commissioned a survey of 75 docs that treat hypogonadism (low testosterone) to help assess the outlook for AUXL's Testim. Overall, the docs expect their prescribing of testosterone replacement (TRT) drugs to grow over the next year, and expect Testim share to decline as LLY's Axiron and ENDP's Fortesta gain share. As always, we caution investors that the views of these docs may not be indicative of the overall market."

Bank of America rated Auxilium a BUY with a price target of $27.00. Auxilium closed Thursday at $18.85.

Posted-In: Auxilium Pharmaceuticals Bank of AmericaAnalyst Color Analyst Ratings


Related Articles (TRT + AUXL)

View Comments and Join the Discussion!

Latest Ratings

PLCEB. Riley FBRDowngrades59.0
ASPUCanaccord GenuityMaintains11.0
AAPLEvercore ISI GroupMaintains305.0
THTXMackie ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

A Peek Into The Market Before The Trading Starts

EA Sports Unveils Global Stars for FIFA Soccer 12